fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

interima analysis of phase III Atalante 1 trial of Tedopi meets endpoint in NSCLC but trial on temporary hold.- OSE Immunotherapeutics

Written by | 2 Apr 2020

OSE Immunotherapeutics announced that the primary endpoint was met in the predefined Step-1 analysis of its Phase III Atalante 1 clinical trial of Tedopi (T-lymphocyte stimulators) in HLA-A2… read more.

Mallinckrodt and Novoteris receive clearance from Health Canada to start a pilot trial of high-dose inhaled nitric oxide therapy for COVID-19 infection and associated complications.- Mallinckrodt + Novoteris LLC

Written by | 2 Apr 2020

Mallinckrodt Plc and Novoteris, LLC, a clinical stage medical device and pharmaceutical developer focused on innovative nitric oxide gas applications, announced that the Therapeutic Products Directorate Of Health… read more.

Synairgen plc initiates Phase II trial of SNG 001 to treat COVID-19 patients .

Written by | 28 Mar 2020

Synairgen plc , the respiratory drug discovery and development company,announces that it has received expedited approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research… read more.

EU gives CE mark approval to SARS-CoV-2 test for Coronavirus.- Thermo Fisher

Written by | 28 Mar 2020

Thermo Fisher Scientific Inc announced that it has received the CE mark in the European Union for its diagnostic test to detect nucleic acid from SARS-CoV-2, the virus… read more.

FDA approves Zeposia to treat relapsing forms of multiple sclerosis ,including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.-BMS

Written by | 28 Mar 2020

Bristol-Myers Squibb Company announced that the FDA approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome,… read more.

EU awards CE mark approval to EBX 041 SARS CoV2 diagnostic test for Coronavirus.- Eurobio Scientific

Written by | 27 Mar 2020

Eurobio Scientific announced CE mark approval for its EBX 041 SARS CoV2 proprietary test, developed specifically for the clinical diagnosis of COVID-19. The EBX 041 SARS CoV2 proprietary… read more.

Zolgensma data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing. – Novartis

Written by | 26 Mar 2020

AveXis, a Novartis company, announced a one-time infusion of Zolgensma (onasemnogene abeparvovec-xioi) showed rapid, significant and clinically meaningful therapeutic benefit in patients with spinal muscular atrophy (SMA) across… read more.

Global Phase II/III trial of Kevzara in patients hospitalized with severe COVID-19 infection .- Regeneron + Sanofi

Written by | 25 Mar 2020

Regeneron Pharmaceuticals, Inc. and Sanofi announced they have started a clinical program evaluating Kevzara (sarilumab) in patients hospitalized with severe COVID-19 infection . Kevzara is a fully-human monoclonal… read more.

FDA grants emergency use authorisation for Xpert Xpress SARS-CoV-2 test for coronavirus.- Cepheid

Written by | 25 Mar 2020

Cepheid announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert Xpress SARS-CoV-2, a rapid molecular diagnostic test for qualitative… read more.

Corevalve reduces rate of death and stroke in aortic stenosis

Written by | 26 Nov 2013

Report from the Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium, 27 October – 1 November, San Francisco.  In a clinical trial, a self-expanding transcatheter aortic valve met the key… read more.

ESC 2013 Report – ACCOAST – Pretreatment with prasugrel before angiography did not improve outcomes and worsened bleeding

Written by | 24 Sep 2013

Among patients with non-ST-segment elevation acute coronary syndrome (ACS), pretreatment with prasugrel before angiography did not improve outcomes and worsened bleeding, a randomized trial showed.

IO Ketamine may lower pain in fibromyalgia

Written by | 20 May 2013

In fibromyalgia patients undergoing knee or hip replacement surgery, low-dose, intraoperative ketamine appeared to reduce the need for post-surgical opioid therapy, researchers said.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.